Detailed examination of PharmaPoint Insomnia – Global Drug Forecast and Market Analysis to 2023
“The Report PharmaPoint: Insomnia – Global Drug Forecast and Market Analysis to 2023 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. – MarketResearchReports.biz”
Insomnia is the most common sleep disorder and is believed to affect approximately 35% of the global population. The condition can be defined as patient-reported difficultly with sleep initiation or sleep maintenance which can include frequent awakenings, difficulty returning to sleep after awakenings, or awakening too early with inability to return to sleep. Cases of insomnia can be classified on the basis of etiology into primary and secondary (or comorbid) subtypes. The insomnia market is widely genericized creating a competitive environment for new products. As such, the treatment algorithm centers on the generically available nonbenzodiazepines and low-dose sedating antidepressants, despite the launch of numerous novel agents. The value of the insomnia market is set to further decline following the loss of exclusivity for Sunovion/Dainippon Sumitomos Lunesta, the top selling insomnia drug, in April 2014. However, GlobalData expects the launch of two pipeline products from a novel class of drugs to provide growth in the insomnia market as they may address some of the unmet need.
View Report At :http://www.marketresearchreports.biz/analysis/277400
Key Questions Answered
The insomnia market is dominated by the generic nonbenzodiazepines and low-does sedating antidepressants. Novel products have not had a significant impact on this market as they lack notable clinical advantages over the current first-line drugs. What are the unmet needs in light of this? Will there be opportunities in this market for drug developers throughout the forecast period?
The current late stage insomnia pipeline is sparse with only one drug having advanced to Phase III. However, GlobalData believes two orexin receptor antagonists will enter the market during the forecast period. What impact will these drugs have on the market? How will they affect the treatment algorithm for insomnia? Will these drugs fulfil any of the unmet needs for insomnia?
Population aging is occurring in almost all countries worldwide, particularly in the 7MM. This is expected to have a significant impact on the prevalence of insomnia. How will epidemiological changes impact the growth of the future insomnia market?
The main driver of growth in the insomnia market will be the introduction of the orexin receptor antagonists over the forecast period. The launch of this novel drug class may address some of the unmet need in the insomnia market due to the safety profile of these drugs and the availability of long-term clinical trial data.
The generic erosion of Lunesta within the insomnia market will lead to a decline in market size prior to the entry of pipeline products. The availability of generic eszopiclone could greatly affect the treatment algorithm and will put downward pricing pressure on the controlled-release zolpidem generics.
The biggest barrier for growth in the insomnia market will be fierce competition from generic products. The commercial advantages to prescribing generic drugs will make it difficult for novel products to gain traction.
Considerable opportunity remains for products that meet the unmet needs in the insomnia market. Drugs with improved safety, which is sustained over the long-term, would hold a competitive advantage. Similarly, drugs that improve sleep quality would be viewed favorably by physicians.
Download Sample copy of this Report at: http://www.marketresearchreports.biz/sample/sample/277400
Overview of insomnia, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
Annualized insomnia market revenue, annual cost of therapy and treatment usage pattern data from 2013 and forecast for ten years to 2023.
Key topics covered include market characterization, unmet needs, R&D and clinical trials assessment, late stage clinical trial analysis and implications for the insomnia therapeutics market.
Pipeline analysis: focus on the three late-stage pipeline insomnia drugs discussing emerging trends as well as overview of earlier phase drugs.
Analysis of the current and future market competition in the global insomnia therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to buy
Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
Additionally a list of acquisition targets included in the pipeline product company list.
Develop business strategies by understanding the trends shaping and driving the global insomnia therapeutics market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global insomnia therapeutics market in future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Track drug sales in the global insomnia therapeutics market from 2013-2023.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Table of Contents
1 Table of Contents
1 Table of Contents 10
1.1 List of Tables 16
1.2 List of Figures 22
2 Introduction 25
2.1 Catalyst 25
2.2 Related Reports 25
3 Disease Overview 26
3.1 Etiology and Pathophysiology 26
3.1.1 Etiology 26
3.1.2 Pathophysiology 32
3.2 Classification 33
3.3 Symptoms 36
3.4 Prognosis 37
4 Epidemiology 38
4.1 Disease Background 38
4.2 Risk Factors and Comorbidities 38
4.3 Global Trends 39
4.4 Forecast Methodology 41
4.4.1 Sources Used 47
4.4.2 Sources Not Used 48
4.4.3 Forecast Assumptions and Methods 49
4.5 Epidemiological Forecast for Acute Insomnia (2013-2023) 58
4.5.1 Total Prevalent Cases of Acute Insomnia 58
4.5.2 Age-Specific Total Prevalent Cases of Acute Insomnia 60
4.5.3 ***-Specific Total Prevalent Cases of Acute Insomnia 61
4.5.4 Age-Standardized Total Prevalence of Acute Insomnia 63
4.6 Epidemiological Forecast for Chronic Insomnia (Not Fulfilling DSM-IV Criteria) (2013-2023) 64
4.6.1 Total Prevalent Cases of Chronic Insomnia (Not Fulfilling DSM-IV Criteria) 64
4.6.2 Age-Specific Total Prevalent Cases of Chronic Insomnia (Not Fulfilling DSM-IV Criteria) 65
4.6.3 ***-Specific Total Prevalent Cases of Chronic Insomnia (Not Fulfilling DSM-IV Criteria) 67
4.6.4 Age-Standardized Total Prevalent Cases of Chronic Insomnia (Not Fulfilling DSM-IV Criteria) 69
4.7 Epidemiological Forecast for Chronic Primary Insomnia (2013-2023) 70
4.7.1 Total Prevalent Cases of Chronic Primary Insomnia 70
4.7.2 Age-Specific Total Prevalent Cases of Chronic Primary Insomnia 71
4.7.3 ***-Specific Total Prevalent Cases of Chronic Primary Insomnia 73
4.7.4 Age-Standardized Total Prevalence of Chronic Primary Insomnia 75
4.8 Epidemiological Forecast for Chronic Secondary Insomnia (2013-2023) 76
4.8.1 Total Prevalent Cases of Chronic Secondary Insomnia 76
4.8.2 Age-Specific Total Prevalent Cases of Chronic Secondary Insomnia 77
4.8.3 ***-Specific Total Prevalent Cases of Chronic Secondary Insomnia 79
4.8.4 Age-Standardized Total Prevalence of Chronic Secondary Insomnia 81
4.9 Discussion 82
4.9.1 Epidemiological Forecast Insight 82
4.9.2 Limitations of the Analysis 83
4.9.3 Strengths of the Analysis 84
5 Disease Management 85
5.1 Diagnosis and Treatment Overview 85
5.1.1 Clinical Evaluation 85
5.1.2 Referral 89
5.1.3 Treatment Guidelines and Leading Prescribed Drugs 89
5.1.4 Clinical Practice 91
5.2 US 95
Follow us on LinkedIn: https://www.linkedin.com/company/marketresearchreports-biz
MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.
90 Sate Street, Suite 700
Albany, NY 12207